DOCSLIB.ORG

Comparison of Intravenous Urapidil and Oral Captopril in Patients with Hypertensive Urgencies

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Comparison of Intravenous Urapidil and Oral Captopril in Patients with Hypertensive Urgencies Journal of Human Hypertension (2006) 20, 707–709 & 2006 Nature Publishing Group All rights reserved 0950-9240/06 $30.00 www.nature.com/jhh RESEARCH LETTER Comparison of intravenous urapidil and oral captopril in patients with hypertensive urgencies Journal of Human Hypertension (2006) 20, 707–709. of the study was prospective, double-blinded and doi:10.1038/sj.jhh.1002063; published online 6 July 2006 both drugs (urapidil and captopril) were given in a double-dummy design, that is, the patient received simultaneously an i.v. agent (either urapidil or In a prospective, double-blinded, double-dummy, sodium chloride 0.9%) and an oral agent (captopril randomized study, 69 patients with a hypertensive or placebo) according to the randomization protocol. urgency (systolic blood pressure (SBP) 4220 mm Hg The primary inclusion criteria was a hypertensive and/or diastolic blood pressure (DBP) 4110 mm Hg) urgency defined as a systolic blood pressure (SBP) received either captopril or urapidil to reduce of 4220 mm Hg and/or a diastolic blood pressure SBP o180 mm Hg and DBP o90 mm Hg and blood (DBP) 4110 mm Hg without evidence of end-organ pressure was measured by an ambulatory blood damage on admission to the emergency department. pressure unit for at least 12 h. The area-under-the- After a resting period of 30 min, blood pressure was curve (AUC) of SBP and DBP was 163 (20)/85 recorded again. If blood pressure was still above (12) mm Hg for the urapidil group and 159 (17)/88 220 mm Hg systolic and/or 110 mm Hg diastolic, (9) mm Hg for the captopril group (P-values 0.38/ patients were finally included to the study. Before 0.40) and the AUC above 180/90 mm Hg was 4.6 the application of the study medication, the patient (4.9)/4.7 (5.7) mm Hg versus 2.7 (5.1)/5.3 (6.3) mm received an ambulatory blood pressure measure- Hg (P ¼ 0.12/P ¼ 0.42) demonstrating that intrave- ment device to record blood pressure every 15 min nous urapidil may be also an useful drug in the for next 12 h. Study medication was given in a treatment of hypertensive urgencies. double-dummy preparation. The patients were Hypertensive urgencies are commonly observed randomized either to urapidil (12.5 mg urapidil i.v. in emergency departments and walk-in-clinics.1 The and placebo oral) or to captopril (25 mg captopril Joint National Committee on Prevention, Detection, oral and 10 ml placebo ( ¼ 0.9% sodium chloride) Evaluation and Treatment of High Blood Pressure as i.v.). Aim of treatment was to reduce SBP below well as the International Society of Hypertension 180 mm Hg and DBP below 90 mm Hg within the (ISH) recommended the use of oral agents for the first hour after study medication was given. Patients treatment of hypertensive urgencies, as blood pres- with a sufficient blood pressure reduction were sure reduction should occur from 6 to 24 h.2,3 In the discharged and instructed to re-admit the emer- setting of an emergency department, a close follow- gency department at least 12 h later. If blood up of these patients is usually impossible. There- pressure was still above 180/90 mm Hg after 1 h, fore, many emergency departments have standard application of the study medication was repeated procedures that prohibit release of patients with (urapidil group: 12.5 mg urapidil i.v./placebo oral; blood pressure in excess of 180/110 mm Hg and treat captopril group: 12.5 mg captopril oral/placebo i.v.) patients with hypertensive urgencies using intrave- and patients were discharged 2 h after start of nous (i.v.) drugs like urapidil or labetalol.4,5 These treatment. The endpoints were the course of SBP drugs reduce blood pressure sufficiently within a and DBP expressed as area-under-the-curve (AUC) short time and with a low frequency of side effects.6 within the first 12 h after drug treatment, the AUC However, these procedures are controversially dis- for SBP and DBP above 180/90 mm Hg, and the cussed and data demonstrating safety and efficacy number of side-effects. of this treatment are lacking. We, therefore, aimed Finally, 56 patients (28 females; 56 (13) years) a study to evaluate the safety and efficacy of an i.v. were included to the study protocol (Table 1). The antihypertensive drug compared to the standard oral average observation period was 11.1 (1.9) h. treatment of patients with hypertensive urgencies. The AUC of SBP and DBP was 163 (20)/85 The study was conducted in the Emergency (12) mm Hg for the urapidil group and 159 (17)/88 Department of the General Hospital in Vienna (9) mm Hg for the captopril group, respectively between March 2004 and October 2004 and was (P-values 0.38/0.40). The course of SBP and DBP approved by the Ethical Committee of the University did not differ significantly between both groups of Vienna. All patients gave their written informed through the entire observation period (Figure 1). consent before inclusion of the study. The design Blood pressure decreased significantly within the Research Letter 708 Table 1 General characteristics of patients in both treatment trolled blood pressure reduction may be harmful in groups patients with hypertensive urgencies. However, the recommendations against the use of i.v. drugs are Urapidil Captopril P-value based on few reports, including a very small number N 27 29 of patients, which have demonstrated severe Age (years) 58 (53–63) 55 (50–61) 0.38 adverse events after the use of drugs like sodium Gender (f/m) 14/13 14/15 0.79 nitroprusside, diazoxide or clonidine.7–10 These Height (cm) 169 (166–173) 169 (166–173) 0.99 drugs are no longer first-line drugs in the treatment Weight (kg) 85 (77–94) 81 (74–88) 0.38 of hypertensive crisis and have been replaced by BMI (kg/m2) 29.4 (27.3–31.4) 28.2 (26.2–30.2) 0.94 Current smokers (n) 12 (44%) 10 (35%) 0.37 newer drugs like urapidil or labetalol. Safety data of these newer drugs used in the treatment of hyper- Hemodynamic data tensive urgencies have been evaluated in different Systolic BP (mm Hg) 216 (208–225) 211 (204–218) 0.23 settings.11 Diastolic BP (mm Hg) 110 (107–117) 110 (105–116) 0.53 Heart rate (beats/min) 97 (89–107) 99 (91–109) 0.94 However, no prospective comparative studies neither with a short-term nor long-term follow-up Abbreviations: BP, blood pressure; BMI, basal metabolic index. using a head-to-head design (i.v. drug versus oral drug) are available: the lack of scientific evidence concerning the benefit or harm of i.v. drugs in the 260 treatment of hypertensive urgencies was the primary 240 reason for the current study. 220 200 For the first time, our study demonstrated a 180 similar safety and efficacy of an i.v. drug in the 160 treatment of hypertensive urgencies compared to an 140 established oral treatment. Additionally, the use of 120 (mm Hg) 100 i.v. urapidil did not cause rapid and uncontrolled 80 blood pressure reduction. We are aware that addi- 60 tional comparative studies in patients with hyper- 40 20 tensive urgencies are required to assess the final 0 value of i.v. drugs in these patients. However, our 0123456789101112 (hours) data demonstrate that the frequently observed use of i.v. drugs in emergency departments is not harmful Figure 1 Course of blood pressure within the first 12 h after the application of urapidil (&) or captopril (K). for patients with hypertensive urgencies. Conflict of interest: None. first hour (urapidil: À46/26 mm Hg; captopril: À38/ 18 mm Hg) in both groups. An increase of blood pressure was observed from the 9th hour after the start of observation in both groups. The AUC above What is known on this topic the defined SBP and DBP of 180/90 mm Hg was 4.6 K Oral antihypertensive drugs are recommended to treat patients (4.9)/4.7 (5.7) mm Hg in the urapidil group and 2.7 with hypertensive urgencies. (5.1)/5.3 (6.3) mm Hg in the captopril group K Data evaluating the efficacy of oral antihypertensive drugs in these patients are rare. (P ¼ 0.12/P ¼ 0.42). Overall, nine adverse effects K No studies are available comparing the efficacy and safety of (urapidil: n ¼ 5; captopril: n ¼ 4) were observed oral and i.v. drugs in this clinical situation. during the study period. The follow-up of the patients after the hypertensive urgency revealed What this study adds K Our data demonstrate a similar efficacy of oral captopril and that 42 patients (urapidil: n ¼ 19; captopril: n ¼ 23) i.v. urapidil in patients with hypertensive urgencies. had elevated blood pressure values either evaluated K No severe side effects have been observed after the application by home blood pressure measurement or 24-h of i.v. urapidil. ambulatory blood pressure measurement. No evi- K Our data provide some evidence that i.v. drugs are not harmful dence of secondary hypertension was observed in in the treatment of hypertensive urgencies. the study group. Our data demonstrate that both drugs are safe and effective in the treatment of patients with hyperten- C Woisetschla¨ger1, A Bur1, M Vlcek1, sive urgencies. The hemodynamic data as well as U Derhaschnig1, AN Laggner1 and MM Hirschl2 the safety data clearly illustrate that the safety and 1Department of Emergency Medicine, University of efficacy of an i.v.
Load more

Recommended publications
  • Product List March 2019 - Page 1 of 53
    Wessex has been sourcing and supplying active substances to medicine manufacturers since its incorporation in 1994. We supply from known, trusted partners working to full cGMP and with full regulatory support. Please contact us for details of the following products. Product CAS No. ( R)-2-Methyl-CBS-oxazaborolidine 112022-83-0 (-) (1R) Menthyl Chloroformate 14602-86-9 (+)-Sotalol Hydrochloride 959-24-0 (2R)-2-[(4-Ethyl-2, 3-dioxopiperazinyl) carbonylamino]-2-phenylacetic 63422-71-9 acid (2R)-2-[(4-Ethyl-2-3-dioxopiperazinyl) carbonylamino]-2-(4- 62893-24-7 hydroxyphenyl) acetic acid (r)-(+)-α-Lipoic Acid 1200-22-2 (S)-1-(2-Chloroacetyl) pyrrolidine-2-carbonitrile 207557-35-5 1,1'-Carbonyl diimidazole 530-62-1 1,3-Cyclohexanedione 504-02-9 1-[2-amino-1-(4-methoxyphenyl) ethyl] cyclohexanol acetate 839705-03-2 1-[2-Amino-1-(4-methoxyphenyl) ethyl] cyclohexanol Hydrochloride 130198-05-9 1-[Cyano-(4-methoxyphenyl) methyl] cyclohexanol 93413-76-4 1-Chloroethyl-4-nitrophenyl carbonate 101623-69-2 2-(2-Aminothiazol-4-yl) acetic acid Hydrochloride 66659-20-9 2-(4-Nitrophenyl)ethanamine Hydrochloride 29968-78-3 2,4 Dichlorobenzyl Alcohol (2,4 DCBA) 1777-82-8 2,6-Dichlorophenol 87-65-0 2.6 Diamino Pyridine 136-40-3 2-Aminoheptane Sulfate 6411-75-2 2-Ethylhexanoyl Chloride 760-67-8 2-Ethylhexyl Chloroformate 24468-13-1 2-Isopropyl-4-(N-methylaminomethyl) thiazole Hydrochloride 908591-25-3 4,4,4-Trifluoro-1-(4-methylphenyl)-1,3-butane dione 720-94-5 4,5,6,7-Tetrahydrothieno[3,2,c] pyridine Hydrochloride 28783-41-7 4-Chloro-N-methyl-piperidine 5570-77-4
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Adrenoceptor Antagonistic Properties of Some 1,4-Substituted Piperazine Derivatives
    ORIGINAL ARTICLES Department of Bioorganic Chemistry, Chair of Organic Chemistry1; Department of Pharmacodynamics2; Department of Cytobiology and Histochemistry, Laboratory of Pharmacobiology3, Faculty of Pharmacy Medical College; Faculty of Chemistry4, Jagiellonian University Krakow, Poland Synthesis, ␣-adrenoceptors affinity and ␣1-adrenoceptor antagonistic properties of some 1,4-substituted piperazine derivatives H. Marona 1, M. Kubacka 2, B. Filipek 2, A. Siwek 3, M. Dybała 3, E. Szneler 4, T. Pociecha 1, A. Gunia 1, A. M. Waszkielewicz 1 Received March 24, 2011, accepted April 25, 2011 Dr. Anna M. Waszkielewicz, Department of Bioorganic Chemistry, Chair of Organic Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna Street, 30-688 Krakow, Poland [email protected] Pharmazie 66: 733–739 (2011) doi: 10.1691/ph.2011.1543 A series of different 1,4-substituted piperazine derivatives (1–11) was synthesized. It comprised 1- (substituted-phenoxyalkyl)-4-(2-methoxyphenyl)piperazine derivatives (1–5); 1,4-bis(substituted-phenoxy- ethyl)piperazine derivatives (6–8) and 1-(substituted-phenoxy)-3-(substituted-phenoxyalkylpiperazin-1- yl)propan-2-ol derivatives (9–11). All compounds were evaluated for affinity toward ␣1- and ␣2-receptors by radioligand binding assays on rat cerebral cortex using [3H]prazosin and [3H]clonidine as specific radioli- gand, respectively. Furthermore ␣1-antagonistic properties were checked for most promising compounds (1–5 and 10) by means of inhibition of phenylephrine induced contraction in isolated rat aorta. Antago- nistic potency stayed in agreement with radioligand binding results. The most active compounds (1–5) 3 displaced [ H]prazosin from cortical binding sites in low nanomolar range (Ki = 2.1−13.1 nM).
    [Show full text]
  • Ep 0665009 A1
    Eu^^esP— || | MMMMI 1 1 1 1 1 1|||| 1 1 1||| || J European Patent Office _ _ _ _ _ © Publication number: 0 665 009 A1 Office europeen desj brevets © EUROPEAN PATENT APPLICATION published in accordance with Art. 158(3) EPC © Application number: 93922625.4 © Int. CI.6: A61 K 9/00 @ Date of filing: 13.10.93 © International application number: PCT/JP93/01469 © International publication number: WO 94/08561 (28.04.94 94/10) ® Priority: 14.10.92 JP 303085/92 Koga-gun, Shiga 520-32 (JP) @ Date of publication of application: Inventor: IZUMI, Shougo 02.08.95 Bulletin 95/31 3-94, Nlshltsutsujlgaoka Mlyamadal 1-chome Kameoka-shl, © Designated Contracting States: Kyoto 621 (JP) AT BE CH DE DK ES FR GB GR IE IT LI LU MC Inventor: OKA, Masaakl NL PT SE 18-8-207, Hoshlgaoka 1-chome Hlrakata-shl, © Applicant: NIPPON SHINYAKU COMPANY, Osaka 573 (JP) LIMITED 14, Klssholn Nlshlnosho Monguchlcho Mlnaml-ku © Representative: Vogeser, Werner, Dipl.-lng. et Kyoto-shl al Kyoto 601 (JP) Patent- und Rechtsanwalte Hansmann, Vogeser, Dr. Boecker, © Inventor: NAKAMICHI, Koulchl Alber, Dr. Strych, Lledl 13-16, Kltayamadal 1-chome, Albert-Rosshaupter-Strasse 65 Koselcho D-81369 Munchen (DE) © CRYSTALLINE CONDITION DISLOCATING METHOD. © An object of this invention is to provide a meth- od of the crystalline condition of dislocating cry- \A/ < stalline medicine simply, speedily and homoge- 4 ^ 0 at neously, and, moreover, in large quantities at once. A X. X O O x.X o °o This invention is directed to a method using an x x.x O outlet side melting zonex cooling zone.
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Screening of 300 Drugs in Blood Utilizing Second Generation
    Forensic Screening of 300 Drugs in Blood Utilizing Exactive Plus High-Resolution Accurate Mass Spectrometer and ExactFinder Software Kristine Van Natta, Marta Kozak, Xiang He Forensic Toxicology use Only Drugs analyzed Compound Compound Compound Atazanavir Efavirenz Pyrilamine Chlorpropamide Haloperidol Tolbutamide 1-(3-Chlorophenyl)piperazine Des(2-hydroxyethyl)opipramol Pentazocine Atenolol EMDP Quinidine Chlorprothixene Hydrocodone Tramadol 10-hydroxycarbazepine Desalkylflurazepam Perimetazine Atropine Ephedrine Quinine Cilazapril Hydromorphone Trazodone 5-(p-Methylphenyl)-5-phenylhydantoin Desipramine Phenacetin Benperidol Escitalopram Quinupramine Cinchonine Hydroquinine Triazolam 6-Acetylcodeine Desmethylcitalopram Phenazone Benzoylecgonine Esmolol Ranitidine Cinnarizine Hydroxychloroquine Trifluoperazine Bepridil Estazolam Reserpine 6-Monoacetylmorphine Desmethylcitalopram Phencyclidine Cisapride HydroxyItraconazole Trifluperidol Betaxolol Ethyl Loflazepate Risperidone 7(2,3dihydroxypropyl)Theophylline Desmethylclozapine Phenylbutazone Clenbuterol Hydroxyzine Triflupromazine Bezafibrate Ethylamphetamine Ritonavir 7-Aminoclonazepam Desmethyldoxepin Pholcodine Clobazam Ibogaine Trihexyphenidyl Biperiden Etifoxine Ropivacaine 7-Aminoflunitrazepam Desmethylmirtazapine Pimozide Clofibrate Imatinib Trimeprazine Bisoprolol Etodolac Rufinamide 9-hydroxy-risperidone Desmethylnefopam Pindolol Clomethiazole Imipramine Trimetazidine Bromazepam Felbamate Secobarbital Clomipramine Indalpine Trimethoprim Acepromazine Desmethyltramadol Pipamperone
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • Søgeprotokol for Nationale Kliniske Retningslinjer
    Søgeprotokol for Nationale Kliniske Retningslinjer Projekttitel/aspekt NKR Demens - Medicin - Primærlitteratur (RCT) Fagkonsulent Anne Mette Skov Sørensen / Elisabeth Bandak Projektleder Casper Larsen Søgespecialist Kirsten Birkefoss Senest opdateret 18.04.2018 Fokuserede spørgsmål : Bør behandling med demenslægemidler seponeres hos PICO 1 personer med meget svær demens? PICO 2: Bør personer med demens i langvarig behandling med antipsykotisk medicin revurderes med henblik på om behandlingen skal fortsætte eller seponeres? PICO 3: Bør personer med demens og søvnbesvær og/eller døgnrytmeforstyrrelse behandles med melatonin? PICO 4: Bør personer med demens og søvnbesvær og/eller døgnrytmeforstyrrelse behandles med mirtazapin eller mianserin? PICO 5: Bør personer med demens i behandling med antidepressiva (> 6 måneder) revurderes med henblik på om behandlingen skal fortsætte eller seponeres? PICO 6: Bør behandling med urologiske spasmolytika med antikolinerg virkning undlades hos personer med demens? PICO 7: Bør man forsøge seponering af paracetamol ved usikker indikation hos personer med demens? PICO 8: Bør man forsøge seponering af opioider ved usikker indikation hos personer med demens? PICO 9: Bør behandlingsmålet for blodtryk være højere hos personer med moderat til svær demens > 80år? Søgetermer Se søgestrategierne under de enkelte PICOs/PIROs Inklusions- og Sprog: Engelsk, tysk, dansk, norsk og svensk eksklusionskriterier År: Se de enkelte PICOs Population: Voksne fra og med 18 år Publikationstyper: RCT 1 Informationskilder DATABASE INTERFACE DATO FOR SØGNING Medline OVID 26.01.2018 - 18.04.2018 EMBASE OVID 26.01.2018 - 18.04.2018 PsycINFO OVID 26.01.2018 - 09.03.2018 CINAHL EBSCO 26.01.2018 - 14.03.2018 Note • Søgetermer og inklusions- og eksklusionskriterier er tilpasset de enkelte databaser.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • ( 19 ) United States
    USOORE48059E (19 ) United States ( 12 ) Reissued Patent (10 ) Patent Number : US RE48,059 E Yamashita et al. ( 45 ) Date of Reissued Patent: * Jun . 23 , 2020 (54 ) PIPERAZINE -SUBSTITUTED 4,734,416 A 3/1988 Banno et al . BENZOTHIOPHENES FOR TREATMENT OF 4,824,840 A 4/1989 Banno et al. 4,831,031 A 5/1989 Lowe, III et al . MENTAL DISORDERS 4,847,254 A 7/1989 Boegesoe et al . 4,883,795 A 11/1989 Lowe, III et al . ( 71) Applicant: Otsuka Pharmaceutical Co., Ltd., 5,006,528 A 4/1991 Oshiro et al . Tokyo (JP ) 5,424,313 A 6/1995 Hartog et al . 5,436,246 A * 7/1995 Bernotas et al . 514 / 252.13 5,506,248 A 4/1996 Nikfar et al . ( 72 ) Inventors : Hiroshi Yamashita , Tokushima ( JP ) ; 5,753,661 A 5/1998 Moltzen et al. Nobuaki Ito , Tokushima ( JP ) ; Shin 5,846,982 A 12/1998 Audia et al. Miyamura , Tokushima (JP ) ; Kunio 5,919,485 A 7/1999 Cochran et al. Oshima, Tokushima (JP ) ; Jun 5,958,924 A 9/1999 McCort et al . 5,977,110 A 11/1999 Belliotti et al . Matsubara , Tokushima ( JP ) ; Hideaki 6,140,331 A 10/2000 Moltzen et al . Kuroda , Tokushima (JP ) ; Haruka 6,187,340 B1 2/2001 Fukuta et al . Takahashi, Tokushima ( JP ) ; Satoshi 6,214,829 B1 4/2001 Feenstra et al. Shimizu , Tokushima ( JP ) ; Tatsuyoshi 6,225,312 B1 5/2001 Feenstra et al. Tanaka , Tokushima ( JP ) ; Yasuo 6,262,056 B1 7/2001 Monge Vega et al . 6,562,375 B1 5/2003 Sako et al.
    [Show full text]
  • Supplemental Figure S1. Positive Correlation of Serum Acid
    Supplemental Figure S1. Positive correlation of serum acid sphingomyelinase (S-ASM) with liver enzyme activities GGT, ALT, and AST in the total cohort (n = 229, a-c) and the subgroup of male (n = 30) but not female (n = 31) healthy controls (d–f). GGT gamma-glutamyl transferase, ALT alanine aminotransferase (glutamic-pyruvic transaminase, GPT), AST aspartate aminotransferase (glutamic-oxaloacetic transaminase, GOT). J. Clin. Med. 2019, 8 2 of 7 Supplemental table S1. Sex-specific demographic and laboratory data for females corresponding to Table 1 for the whole groups. See legend of Table 1 for details. p values for group difference Parameters PU PM PR HC PU vs. PM PU vs. HC PM vs. HC PR vs. HC n at inclusion 36 32 31 28 n at follow-up 34 28 age (years) 45 (33–53) 46 (32–55.5) 52 (47–63) 47 (32–60) 0.810 0.642 0.645 0.109 total education years a 15 (13–17) 14 (12–17) 14 (12–15) 14 (12–17) 0.216 0.527 0.585 0.792 BMI (kg/m²) 24.0 (21.3–27.3) 27.3 (22.1–30.6) 25.3 (22.7–29.2) 24.3 (23–26.2) 0.055 0.664 0.124 0.309 BDI-II score at inclusion 29 (21–36) 33 (27–39) 3 (0–5) 1 (0–4) 0.176 <0.001 <0.001 0.368 BDI-II score at follow-up c 22 (15–27) 24 (16–36) 0.318 BDI-II score at relative change c −0.23 (–0.42–−0.06) −0.21 (−0.42–−0.01) 0.955 HAM-D score at inclusion 22 (19–26) 24 (21–27) 2 (1–4) 1 (0–3) 0.095 <0.001 <0.001 0.256 HAMD-D score at follow-up c 18 (14–21) 17 (11–22) 0.804 HAMD-D score at relative change c −0.24 (−0.38–−0.05) −0.24 (−0.44–−0.08) 0.471 MADRS score at inclusion 26 (22–28) 28 (25–35) 1 (0–4) 1 (0–2) 0.046 <0.001 <0.001
    [Show full text]
  • WO 2007/061529 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date (10) International Publication Number 31 May 2007 (31.05.2007) PCT WO 2007/061529 Al (51) International Patent Classification: GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, A61K 9/14 (2006.01) KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV,LY,MA, MD, MG, MK, MN, MW, MX, MY, MZ, (21) International Application Number: NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, PCT/US2006/040197 SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW (22) International Filing Date: 13 October 2006 (13.10.2006) (84) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (26) Publication Language: English ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT,BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV,MC, NL, PL, PT, (30) Priority Data: RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, 11/282,507 18 November 2005 (18.1 1.2005) US GN, GQ, GW, ML, MR, NE, SN, TD, TG). (71) Applicant (for all designated States except US): SCI- Declarations under Rule 4.17: DOSE PHARMA INC.
    [Show full text]